The main purpose of the study is to evaluate empasiprubart use in adults living with Multifocal Motor Neuropathy (MMN). The researchers will evaluate the effect of empasiprubart on the thickness of the nerves, muscle strength, movement, and on the potential improvement of grip strength of the participants in handling objects.
The study consists of an open-label treatment period where all participants will receive empasiprubart intravenously (IV). After the last dose of empasiprubart participants will enter a safety follow-up period for up to 15 months.
The total study duration for each participant will be approximately 29 months.
More information can be found here: clinicaltrials.argenx.com/empasound
Is at least 18 years old
Diagnosed with MMN
Has an MMN-RODS centile score of ≤90
Has confirmed nerve thickening in at least 1 nerve per ultrasound measurement
Besides the indication under study, known autoimmune disease or any medical condition that, in the investigator's opinion, would interfere with an accurate assessment of clinical symptoms of MMN or puts the participant at undue risk.